EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies
Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in…